Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340989 | 0.98 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HTTHRH3KDM4E | |
| SCHEMBL17896855 | 0.86 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HTTHRH3KDM4E | |
| SCHEMBL15587428 | 0.86 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HTTHRH3KDM4E | |
| SCHEMBL1936493 | 0.86 | PRMT6 (0.61) | ALDH1A1SMN1; SMN2HTTHRH3KDM4E | |
| SCHEMBL10315541 | 0.85 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HTTHRH3KDM4E | |
| SCHEMBL17096000 | 0.85 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HTTHRH3KDM4E | |
| SCHEMBL8806332 | 0.83 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL17896312 | 0.82 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HTTHRH3KDM4E | |
| SCHEMBL2238993 | 0.82 | NCF1 (0.62) | ALDH1A1SMN1; SMN2HTTHRH3KDM4E | |
| SCHEMBL28588829 | 0.81 | MEN1 (0.69) | ALDH1A1SMN1; SMN2KDM4ETDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951660-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8389743-B2 | Histamine-3 receptor antagonists | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120220568-A1 | Histamine-3 Receptor Antagonists | PFIZER INC. | 2012-08-30 | — | — | US | disclosed |
| US-8158673-B2 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | PFIZER INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1951660-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080096955-A1 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | PFIZER INC | 2008-04-24 | — | — | US | disclosed |
| WO-2007049123-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096955-A1 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | HRH3, HRH4, HRH2 | ALDH1A1 1257/4885SMN1; SMN2 1300/4885HTT 129/4885 |
| US-20120220568-A1 | Histamine-3 Receptor Antagonists | HRH3, HRH4, HRH1 | ALDH1A1 1965/4885SMN1; SMN2 1813/4885HTT 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.